PHGE — BiomX Inc.
—
NYSE ·
Health Care ·
Biotechnology ·
CIK 1739174 ·
Last close
$0.54
Market Cap
$5.98M
52W High
$6.75
52W Low
$0.36
ADV30
12,353,617
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -1,296,000 | -19,140,000 | 3,251,000 | 1,168,000 | 4,132,000 |
| Dec 2025 | 0 | — | -7,195,000 | -13,337,000 | 5,783,000 | 4,360,000 | 7,085,000 |
| Sep 2025 | 0 | — | -8,536,000 | -9,166,000 | 26,168,000 | 6,923,000 | 15,682,000 |
| Jun 2025 | 0 | — | -7,433,000 | -6,037,000 | 38,050,000 | 14,046,000 | 18,890,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-23,092,000
Investing CF
$-939,000
Financing CF
$3,899,000
CapEx
$-21,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-22.77
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-236,036,000
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-48,188,000
Pretax Income TTM
$-47,674,000
Interest Exp TTM
$-514,000
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -30,920,000 | -36,199,000 | 5,783,000 | 7,085,000 | — | -26,390,000 |
| Dec 2024 | 0 | -35,551,000 | -17,727,000 | 43,233,000 | 19,085,000 | — | -36,979,000 |
| Dec 2023 | 0 | -25,348,000 | -26,169,000 | 25,029,000 | 21,948,000 | — | -21,286,000 |
| Dec 2022 | 0 | -27,219,000 | -28,317,000 | 45,531,000 | 24,492,000 | — | -29,092,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-6.01
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BCAB | BioAtla, Inc. | $6.41M | $3.86 | — |
| LIMN | Liminatus Pharma, Inc. | $5.48M | $0.12 | — |
| CPMV | Mosaic ImmunoEngineering Inc. | $4.88M | $0.67 | — |
| CELZ | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. | $8.02M | $2.17 | — |
| PMCB | PharmaCyte Biotech, Inc. | $8.17M | $0.76 | — |
News headlines (Yahoo Finance, 1h cache)
BiomX Announces NYSE American Acceptance of Plan to Regain Compliance
2026-06-12 13:00 · Yahoo
BiomX: Zorronet’s AI Security Experts Provide In-Depth Review on Why Security AI Must Move Beyond Detection to Understanding in High-Stakes Global Events
2026-06-11 13:03 · Yahoo
Another Prominent Defense Technology Leader Joins BiomX: Prof. Gabby Sarusi, Former VP and Chief Scientist at Elbit
2026-06-02 13:32 · Yahoo
Zorronet Brings Autonomous C5ISR to Hardened Sites Without Public Cloud Dependence
2026-06-01 13:25 · Yahoo
BiomX Appoints IDF Colonel (res.) Roy Timor-Rousso as Chief Business Officer to Strengthen Defense & Security Operations
2026-05-27 13:40 · Yahoo
BiomX’s Zorronet Puts Full AI Command-and-Control in the Palm of Your Hand
2026-05-06 20:15 · Yahoo
Zorronet Delivers 98% Success in Israel Railways Pilot, Awarded Framework Supply Agreement for AI-Powered Detection Systems
2026-04-16 20:30 · Yahoo
BiomX Accelerates Defense Technology Buildout with DFSL Acquisition
2026-04-13 13:20 · Yahoo
BiomX Acquires Zorronet, Autonomous AI Command-and-Control Platform for Real-Time Defense and Security Applications
2026-04-10 12:30 · Yahoo
BiomX Obtains Option to Acquire Control of Israeli Laser-Radar Counter-Drone System
2026-03-31 14:48 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.